PPARG and colitis: In mouse models of colitis, it was observed that PPARG agonists can shift the immune response from a Th1-type to a Th2-type, resulting in a decrease in the expression of Th1-associated transcription factors, cytokines, and chemokines, and simultaneously an increase in the expression of Th2-associated factors (Celinski et al., 2013; Saubermann et al., 2002).